Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs Nu Holdings Ltd (NU) Price & Performance

Davita IncTrade
Nu Holdings LtdTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs Nu Holdings Ltd — how do they compare? Davita Inc trades at $178.01 (market cap $11.29B), while Nu Holdings Ltd trades at $15.6 (market cap $74.30B). The key difference: Nu Holdings Ltd is far larger — about 6.6× Davita Inc's market cap, and Davita Inc is more actively traded (582,204 versus 80,294,805). Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Nu Holdings Ltd for 53 Days on average.

DVANU
Market Cap
$11.29B$74.30B
Volume
582,20480,294,805
Sector
HealthFinancials
52-Week High
$240.96$18.76
52-Week Low
$103.87$11.60
Typical Hold Time
113 Days53 Days
Enterprise Value
$24.01B$96.91B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.

DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.

Nu Holdings Ltd

NU Holdings (NU) trades at $15.58, down 0.51% on the day, with strong fundamental momentum despite recent volatility. The stock shows bullish technical signals with moving averages supporting upward trends, while oscillators indicate some near-term pressure. Revenue growth has accelerated from $3.0B in 2022 to $10.6B in 2025, with net income turning positive and reaching $2.9B. Recent news highlights acquisition speculation and Goldman Sachs' bullish stance, though the company denied Monzo deal talks.

The outlook remains positive with 56.5% analyst buy ratings and a $16.53 consensus target offering 6% upside. Key opportunities include expanding Latin American digital banking penetration and strong profitability metrics (27.4% net margin). Risks include credit quality concerns from rising delinquencies and competitive pressures in fintech. The stock presents a growth opportunity but requires monitoring of execution risks and market sentiment shifts.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DVA
91% Buy9% Sell
Avg holding period · 113 Days
NU
30% Buy70% Sell
Avg holding period · 53 Days

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA →

About Nu Holdings Ltd

Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.

Read more on NU →